Open access
Outcome after first relapse post‐immunochemotherapy in older adults with Philadelphia‐negative B‐cell acute lymphoblastic leukemia: A GRAALL study
Perrine Moyer
T. Leguay
M. Jullien
Françoise Huguet
Gabrielle Roth Guepin
Y. Hicheri
A. Belhabri
T. Cluzeau
A. Berceanu
Emmanuelle Tavernier
S. Leprêtre
K. Bilger
Pascal Turlure
J. Bastie
M. Balsat
M. Alexis
E. Brissot
D. Lebon
Emmanuel Raffoux
S. Wickenhauser
V. Cacheux
A. Banos
Sarah Bonnet
N. Boissel
Hervé Dombret
P. Rousselot
P. Chevallier
Medicine
Abstract
Inotuzumab (InO)‐based frontline regimens have significantly improved the survival of older patients with Philadelphia‐negative (Ph–) B‐cell acute lymphoblastic leukemia (B‐ALL). Yet, outcome after relapse is not reported for this population.